Biotech | November 20, 2021
Novo Nordisk to acquire Dicerna Pharmaceuticals for US $ 3.3 bn
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
Dicerna develops RNAi-based therapies to selectively silence genes that cause or contribute to disease
It is anticipated to be safe and efficacious by targeting the receptor-binding domain (RBD) of the new coronavirus
The system is a compact new addition to the Roche Molecular portfolio, providing efficiency, simplicity and timely results to laboratories of all sizes.
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Launching in 2022, its availability will be expanded to the global market
Solara Active Pharma Sciences has reported consolidated financial results for the period ended September 30, 2021.
The Board of Directors of Alembic Pharmaceuticals have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021.
Metropolis Healthcare has reported consolidated financial results for the period ended September 30, 2021
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
The Board of Directors of AstraZeneca Pharma India have approved the unaudited consolidated financial results of the company for the period ended September 30, 2021
Subscribe To Our Newsletter & Stay Updated
